Intermittent versus Daily Therapy for Noncavitary <i>Mycobacterium avium</i> Complex Pulmonary Disease: An Open-Label Randomized Trial.

ABSTRACT: Rationale: Patients with noncavitary nodular bronchiectatic (NB) Mycobacterium avium complex pulmonary disease (MAC-PD) are treated intermittently three times per week, although no randomized controlled trials have been conducted comparing three times weekly with daily therapy. Objectives: To assess the tolerability, safety, and efficacy of intermittent versus daily treatment in patients with previously untreated noncavitary NB MAC-PD. Methods: In an open-label study, patients were randomly assigned to the intermittent therapy group receiving clarithromycin 1,000 mg, rifampicin 600 mg, and ethambutol 25 mg/kg (maximum 1,000 mg) three days per week or the daily therapy group receiving clarithromycin 800 mg, rifampicin 450 mg, and ethambutol 15 mg/kg (maximum 750

SUBMITTER: Nakagawa T 

PROVIDER: S-EPMC12329335 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature